Filing Flows › Cytek Biosciences (CTKB) › Q2 2026 › vs Q2 2025
Cytek Biosciences (CTKB) Q2 2026 vs Q2 2025 (year over year)
Cytek Biosciences's revenue rose $2.5M (+6%) from $45.6M in Q2 2025 to $48.1M in Q2 2026. The biggest changes: Service +$1.4M (+10%); Product +$1.1M (+4%).
Cytek Biosciences, Q2 2026: revenue $48.1M (+6% year over year), operating margin -23.7%, net loss $12.2M, operating cash flow $1.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $32.6M | $31.4M | $1.1M | +4% |
| Service | $15.6M | $14.2M | $1.4M | +10% |
| Revenue | $48.1M | $45.6M | $2.5M | +6% |
| Net loss | $12.2M | $5.6M | $6.6M | +118% |
| Costs & expenses | $60.3M | $56.2M | $4.1M | +7% |
| Operating costs | $59.5M | $56.2M | $3.3M | +6% |
| Interest & other, net | $243K | −$3.8M | $4.1M | — |
| Income tax | $515K | −$1.2M | $1.7M | — |
| Cost of revenue | $19.8M | $21.7M | −$1.9M | -9% |
| Research & development | $9.7M | $8.8M | $915K | +10% |
| Sales & marketing | $13.2M | $12.1M | $1.0M | +9% |
| General & admin | $16.8M | $13.5M | $3.3M | +24% |
| Operating cash sources | $13.5M | $5.7M | $7.8M | +138% |
| Depreciation & amortization | $2.0M | $1.9M | $119K | +6% |
| Share-based compensation | $5.3M | $6.8M | −$1.5M | -21% |
| Working capital & other | $6.2M | −$3.0M | $9.2M | — |
| Net loss absorbed | $12.2M | $5.6M | $6.6M | +118% |
| Operating cash flow | $1.4M | $108K | $1.3M | 13× |
| Capital expenditures | $2.2M | $1.6M | $639K | +41% |
| Negative free cash flow (OCF − capex) | $849K | $1.5M | −$620K | -42% |
Questions
How much did Cytek Biosciences's revenue grow year over year in Q2 2026?
Cytek Biosciences's revenue rose $2.5M (+6%) from $45.6M in Q2 2025 to $48.1M in Q2 2026.
What drove Cytek Biosciences's revenue change in Q2 2026?
Service +$1.4M (+10%); Product +$1.1M (+4%).